OPEN END TURBO OPTIONSSCHEIN LONG - VERTEX PHARMACEUTICALS | Real-time BOERSE MUENCHEN 06:25:25 2024-06-21 am EDT | ||
| 14.71 EUR | +0.75% |
|
| Current month | +15.51% | ||
| 1 month | +17.65% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-21 | 14.71 | +0.75% |
| 24-06-20 | 14.6 | +2.67% |
| 24-06-19 | 14.22 | -1.80% |
| 24-06-18 | 14.48 | -4.55% |
| 24-06-17 | 15.17 | -3.19% |
Real-time BOERSE MUENCHEN
Last update June 21, 2024 at 06:25 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GK9DJX |
| ISIN | DE000GK9DJX7 |
| Date issued | 2022-08-22 |
| Strike | 315.8 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.19 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 15.84 € |
|---|---|
| Lowest since issue | 0.74 € |
| Spread | 0.1 € |
| Spread % | 0.68% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
471.4
USD
Average target price
463.4
USD
Spread / Average Target
-1.69%
- Stock Market
- Certificates
- Certificat
